Document Detail


Anaemia of prematurity. Epidemiology, management and costs.
MedLine Citation:
PMID:  10174310     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Recombinant human erythropoietin (rHuEpo) has been increasingly used in preterm infants in the last 3 to 4 years. Recent studies have indicated a reduction in blood transfusion requirements in infants receiving rHuEpo. No significant adverse effects have emerged, apart from iron deficiency (if iron supplementation is inadequate), and the risk of transfusion-related infection is decreased. Nevertheless, rHuEpo is relatively expensive (a 6-week course costs approximately the same as 2 blood transfusions), so its use requires careful consideration; it is logical to target rHuEpo therapy to those babies who are most likely to be transfused. Using this strategy, 1 study involving stable growing preterm infants has shown that direct costs of blood transfusion and rHuEpo were similar, and the use of rHuEpo was recommended. In addition, use of high-dosage rHuEpo early in the course of management on the neonatal intensive care unit has been shown to reduce direct treatment costs in ill preterm infants. Further studies will continue to identify infants who are likely to benefit from rHuEpo therapy and to define its cost effectiveness in more detail.
Authors:
M P Meyer
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  PharmacoEconomics     Volume:  12     ISSN:  1170-7690     ISO Abbreviation:  Pharmacoeconomics     Publication Date:  1997 Oct 
Date Detail:
Created Date:  1997-11-26     Completed Date:  1997-11-26     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  9212404     Medline TA:  Pharmacoeconomics     Country:  NEW ZEALAND    
Other Details:
Languages:  eng     Pagination:  438-45     Citation Subset:  T    
Affiliation:
Special Care Baby Unit, Middlemore Hospital, Auckland, New Zealand. mmeyer@ww.co.nz
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anemia, Neonatal / economics*,  epidemiology,  therapy*
Erythropoietin, Recombinant / adverse effects,  economics*,  therapeutic use*
Humans
Infant
Infant, Newborn
Infant, Premature, Diseases / economics*,  epidemiology,  therapy*
Chemical
Reg. No./Substance:
0/Erythropoietin, Recombinant

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Treating myocardial infarction in the post-GUSTO era. A European perspective.
Next Document:  The costs of epilepsy and cost-based evaluations of anticonvulsants.